Related Experiment Videos
Cancer vaccines targeting the HER2/neu oncogenic protein
1Division of Oncology, University of Washington, Seattle, WA 98195-6527, USA.
Abstract:
Several advances in basic immunology over the last few years have forced a re-evaluation of cancer vaccine development. The most important finding has been that human tumors are immunogenic. The HER2/neu oncogenic protein is a tumor antigen. Existent antibody, helper T-cell, and cytotoxic T-cell immunity to HER2/neu have been detected in patients with cancer. The HER2/neu protein is an excellent therapeutic target for the immune system. Passive immunotherapy strategies, such as the infusion of monoclonal antibodies specific for HER2/neu, have been shown to be of clinical benefit in patients with HER2/neu-overexpressing malignancies. Inducing an active immune response by generating endogenous HER2/neu-specific antibodies and T cells may result in long-lived immunity and, hopefully, therapeutic benefit. In the majority of patients with pre-existent HER2/neu immunity, the antigen-specific antibodies and T cells detected are of low magnitude. Therefore, vaccine strategies aimed at boosting immunity already present may be effective in generating significant levels of HER2/neu-specific antibodies and T cells.
Insights
Human tumors are immunogenic, with the HER2/neu protein serving as a key tumor antigen. Cancer vaccines can boost existing HER2/neu immunity for therapeutic benefit.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Recent advances in immunology reveal that human tumors possess immunogenic properties.
- The HER2/neu oncogenic protein is identified as a significant tumor antigen.
- Pre-existing immunity, including antibodies and T-cells targeting HER2/neu, is observed in cancer patients.
Purpose of the Study:
- To re-evaluate cancer vaccine development strategies based on new immunological findings.
- To explore the therapeutic potential of targeting the HER2/neu protein using active immunotherapy.
- To investigate the efficacy of boosting pre-existing HER2/neu immunity through vaccination.
Main Methods:
- Analysis of existing immunological data regarding HER2/neu in cancer patients.
- Review of passive immunotherapy strategies utilizing HER2/neu-specific monoclonal antibodies.
- Conceptual framework for active immunotherapy via vaccine-induced HER2/neu-specific immune responses.
Main Results:
- Human tumors are immunogenic, with HER2/neu identified as a targetable tumor antigen.
- Passive immunotherapy with HER2/neu antibodies shows clinical benefit in relevant malignancies.
- Pre-existing HER2/neu immunity in patients is typically of low magnitude.
Conclusions:
- The HER2/neu protein represents a viable therapeutic target for the immune system.
- Active immunotherapy, by boosting existing HER2/neu immunity, holds promise for generating significant anti-tumor responses.
- Vaccine strategies focused on enhancing low-level HER2/neu immunity may lead to long-lived and therapeutic immune benefits.